Tuesday, 18 February 2020

Japan News

  • Japan gives patent for Medgenics IFNa pump

    Japan |  News | By BioSpectrum Bureau  | 0 Comment | 07 Dec, 2012

    Singapore: Medgenics received a Notice of Allowance from the Japanese Patent and Trademark Office for key claims protecting the use of Medgenics' Infradure Biopump technology for the deli...Read more

  • Novel oral RA treatment Xeljanz launched in Japan

    Japan |  News | By BioSpectrum Bureau  | 0 Comment | 06 Aug, 2013

    Singapore: Pfizer Japan and Takeda Pharmaceutical have launched Xeljanz (tofacitinib citrate) in Japan. The medicine was approved by the Japanese Ministry of Health, Labour and Welfare (MHL...Read more

  • Japan firms keen to collaborate with Indian pharma

    Japan |  News | By BioSpectrum Bureau  | 0 Comment | 14 Feb, 2013

    Singapore: Japanese companies are keen to collaborate with pharmaceutical companies in India. A delegation of pharmaceutical firms from Japan's Toyama prefecture was in New Delhi on June 13...Read more

  • Astellas to pay $300 mn for cancer drug conjugates

    Japan |  News | By BioSpectrum Bureau  | 0 Comment | 05 Apr, 2013

    Singapore: Japan's Astellas Pharma has collaborated with US-based Ambrx for the discovery and development of novel antibody drug conjugates (ADCs), which allow for the targeted delivery of ...Read more

  • Eisai dissolves Palma Bee'Z Research Institute

    Japan |  News | By BioSpectrum Bureau  | 0 Comment | 11 Oct, 2012

    Singapore: Japan-headquartered Eisai and its diagnostics business subsidiary Eidia have decided to dissolve and absorb their jointly owned diagnostics research and development subsidiary, P...Read more

  • Shimadzu extends ultra fast mass spectrometry range

    Japan |  News | By BioSpectrum Bureau  | 0 Comment | 08 Aug, 2012

    Singapore: Shimadzu UK has launched a high-end liquid chromatography mass spectrometer, the LCMS-8080, which delivers best-in-class sensitivity, high quality data and fast cycle times. An e...Read more

  • Takeda seeks bowel drug marketing nod from EU

    Japan |  Regulatory | By BioSpectrum Bureau  | 0 Comment | 08 Mar, 2013

    Singapore: Takeda Pharmaceutical submitted a marketing authorization application (MAA) to the European Medicines Agency (EMA) for vedolizumab, an investigational, gut-selective humanized mo...Read more

  • Japan approves Accent MRI Pacemaker

    Japan |  Regulatory | By BioSpectrum Bureau  | 0 Comment | 02 Jul, 2013

    Singapore: St Jude Medical, a global medical device company, has received approval from the Japanese Ministry of Health, Labour and Welfare (MHLW) to launch the Accent MRI Pacemaker and the...Read more

  • Japan, Korea lead in stem cell race

    Japan |  Opinion | By Nandita Singh | 0 Comment | 12 Nov, 2012

    In South Korea, two research teams led by Prof. Park Se-pill at Jeju National University Stem Cell Research Center and Mirae Biotech used non-viral vectors of nanoparticles and liposomal ma...Read more

  • Exlites eyes more medtech deals from China, Taiwan, Japan

    Japan |  News | By BioSpectrum Bureau  | 0 Comment | 13 Aug, 2013

    Singapore: Exlites Holdings from the US has entered into an agreement with a company that will source new cutting edge medical products from China, Taiwan and Japan. Exlites has gone into a...Read more

  • NZ value-added dairy product launches in Japan

    Japan |  News | By BioSpectrum Bureau  | 0 Comment | 13 Jun, 2013

    Singapore: New Zealand-based dairy biotechnology company, Quantec, announced that it has signed a distribution and supply agreement with a major Japanese specialty ingredients company, Kane...Read more

  • Otsuka schizophrenia relapse gets FDA nod

    Japan |  Regulatory | By BioSpectrum Bureau  | 0 Comment | 01 Mar, 2013

    Singapore: Japan-based Otsuka Pharmaceutical and H Lundbeck have received US FDA approval for Abilify Maintena (aripiprazole) extended-release injectable suspension, an intramuscular (IM) d...Read more

  • US FDA issues API bulk & tapped density guidance

    Japan |  Regulatory | By BioSpectrum Bureau  | 0 Comment | 11 Jul, 2013

    Singapore: The US Food and Drug Administration (FDA) has issued guidance to the Active Pharmaceutical ingredient industry on bulk density and tapped density of powders. The norms revolve a...Read more

  • Dezima in-licenses CETP inhibitor from Mitsubishi

    Japan |  News | By BioSpectrum Bureau  | 0 Comment | 29 Jan, 2013

    Singapore: Dezima Pharma, a biotechnology company developing innovative drugs in the field of dyslipidemia, has in-licensed a cholesteryl ester transfer protein (CETP) inhibitor DEZ-001 (fo...Read more

  • South Korea approves Halaven for breast cancer

    Japan |  News | By BioSpectrum Bureau  | 0 Comment | 05 Sep, 2012

    Singapore: Eisai's South Korean sales subsidiary has received approval from the regulatory authorities in South Korea to market the anticancer agent Halaven (eribulin mesylate) for the trea...Read more

  • Takeda's foreign recruitments suffer hostility

    Japan |  News | By BioSpectrum Bureau  | 0 Comment | 24 Jun, 2014

    Singapore: The former executives and shareholders of Takeda, a leading Japanese firm, have expressed their resentment over recruitment of foreigners to govern senior positions of the concer...Read more

  • Orexo re-submits NDA for cancer pain killer in Japan

    Japan |  News | By BioSpectrum Bureau  | 0 Comment | 19 Nov, 2012

    Singapore: Swedish specialty pharmaceutical company, Orexo, revealed that that its partner Kyowa Hakko Kirin submitted a new drug application (NDA) in Japan for KW-2246 (Abstral), a fentan...Read more

  • Eisai reveals phase III results of breast cancer drug Halaven

    Japan |  News | By BioSpectrum Bureau  | 0 Comment | 10 Jul, 2012

    Singapore: Eisai revealed its preliminary results from a recently completed phase III study of Halaven versus capecitabine (Xeloda) in women with locally advanced or metastatic breast cance...Read more